contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


ascelia-pharma-rettet-emission-pa-cirka-sek-30-mio

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Equity Research Analyst

Philip Coombes

CEO, Sweden

Claus Thestrup

Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detecting and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.

Ascelia Pharma is listed on Nasdaq Small Cap Stockholm with ticker ACE.

Ascelia Pharma

Ascelia Pharma har gennemført en rettet emission på cirka SEK 30 mio. Kapitalen sikrer finansiering frem til Q4 2026 og understøtter partnerskabsaktiviteter forud for FDA’s afgørelse om Orviglance. Emissionen medfører en udvanding på ~6,8 %, men reducerer den finansielle risiko og giver selskabet fleksibilitet på et afgørende tidspunkt.

Selskabet har gennemf&#xf8;rt en rettet emission p&#xe5; ca. 30 mio. SEK. Kapitalen sikrer finansiering frem til Q4 2026 og underst&#xf8;tter partnerskabsaktiviteter forud for FDA&#x2019;s afg&#xf8;relse om Orviglance. Emissionen medf&#xf8;rer en udvanding p&#xe5; ~6,8 %, men reducerer den finansielle risiko og giver selskabet fleksibilitet p&#xe5; et afg&#xf8;rende tidspunkt.
Hvorfor nu og hvad skal bel&#xf8;bet bruges til?
<ul data-start="543" data-end="992">
<li data-start="543" data-end="643">
Styrke balancen og sikre driftskapital frem mod Q4 2026&#xa0;
</li>
<li data-start="644" data-end="864">
Underst&#xf8;tte forhandlingerne med potentielle partnere og sikre finansiering frem til den forventede FDA-beslutning i forbindelse med den nyligt indsendte New Drug Application (NDA)
</li>
<li data-start="865" data-end="992">
Udvide investorbasen med nye&#xa0; svenske og internationale institutionelle investorer
</li>
</ul>
Emissionen virker strategisk rigtig for at sikre, at Ascelia Pharma kan forts&#xe6;tte sin udvikling, is&#xe6;r med hensyn til FDA-processen, uden at l&#xf8;be t&#xf8;r for kapital inden Q4 2026.&#xa0;
L&#xe6;s hele meddelelsen her:<a href="https://www.ascelia.com/mfn_news/ascelia-pharma-has-completed-a-directed-share-issue-of-approximately-sek-30-million/" target="_blank" rel="noopener">Ascelia Pharma Has Completed a Directed Share Issue of Approximately SEK 30 Million</a>
Disclaimer: HC Andersen Capital modtager betaling fra Ascelia Pharma for en Digital IR-abonnementsaftale./Claus Thestrup 23.09.2025, kl. 7:34